ß-adrenoblockers in essential hypertension: Overview of the third millenium
https://doi.org/10.18705/1607-419X-2005-11-1-13-16
Abstract
About the Authors
A. O. KonradiRussian Federation
E. R. Berngardt
Russian Federation
Ye. N. Smirnova
Russian Federation
References
1. Mac Mahon N.B., Саитап S. Effects of АСЕ inhibitors, calcium antagonists, and other blood pressure lowering drugs: results of prospectively designed overviews of randomized trials. BPLTCT. Lancet 2004;345:1076-78.
2. Pollare T, Lithell H, Selinus I et al. Sensitivity to insulin during treatment ivith atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. Br Med J 1989;298:1152-7.
3. Jacob S., Rett K., Wicklmayr M. et al. Differential effect of chronic treatment with two betablocking agents on insulin sensitivity : the carvedilol-metoprolol study. J Hypertens 1996;14:489-94
4. Garlberg B., Samuelsson O., Lindholm L.H. Atenolol in hypertension: is it a wise choice? Lancet 2004;3б4:1684-9·
5. Panza J.A., Quyyumi A.A., Brush J.E. et al. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990;323:22-7.
6. Lyons D., Webster J., Benjamin N. The effect of antihypertensive therapy on responsiveness to local intra-arterial N-Monometyl-L-Arginin in patients with essential hypertension. J Hypertens 1994;12:1047-52.
7. Galderisi M., Cicala S , D’Errico A. et al. Nebivolol improves coronary flow reserve in hypertensive patients without coronary artery disease J Hypertension 2004;22:2201 -9.
8. Messerli F.H., Grossman E., Goldbourt U. Are b-blockers efficacious as firstline therapy for hypertension in the elderly? A systematic review. JAMA 1998;279:1903-7.
9. Rabkin S.W. Mechanisms of action of adrenergic receptor blockers on lipids during antihipertensive drug treatment. J Clin Pharmacol 1993;33:286-91.
10. Reneland R., Alvarez E., Andersson P.E. et al. Induction of insulin resistance by beta-blockade but not ACE-inhibition: long-term treatment with atenolol or trandolapril.J Hum Hypertens 2000;14(3):175-80.
11. Messerli F., Grossman E., Leonetti G. Antihypertensive therapy and new onset diabetes. J Hypertens 2004;22:1845- 7.
12. Broeders M.A., Doevendans P.A., Bekkers B.C. et al. Nebivolol: a third-generation beta-blocker that augments vascular nitnc oxide release: endothelial beta (2)- adrenergic receptor-mediated nitnc oxide production. Circulation 2000; 102 (Suppl.6):677-84.
13. Бернгардт Э.Р., Конради A.O., Смирнова Е.В., Панов A.B. Влияние ß-адреноблокаторов с вазодилатирующими и без вазодилатирующих свойств на показатели липидного, углеводного обмена и инсулинорезистентность. Открытое рандомизированное сравнительное исследование терапии небивололом и надололом больных гипертонической болезнью и избыточной массой тела.Артериальн. гипертензия. 2001;9:78-85-
14. Wink К. Are beta-blockers efficacious as first-line therapy for hypertension in the elderly?J Clin Basic Cardiol 2001;4:235-8.
15. Flather M.D., Shibata M.C., Coats AJS et al. Randomized trail to determine the effect of Nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005;26:215-25.
Review
For citations:
Konradi A.O., Berngardt E.R., Smirnova Ye.N. ß-adrenoblockers in essential hypertension: Overview of the third millenium. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2005;11(1):13-16. (In Russ.) https://doi.org/10.18705/1607-419X-2005-11-1-13-16